Medical communications agency serving global biopharma with scientific content and regulatory expertise
Cactus Life Sciences is a medical communications firm serving the biopharma industry from Princeton with offices across Switzerland, UK, India, and Japan. The hiring mix—skewed toward marketing (11 roles) and senior staff (11 roles)—combined with active projects around account team setup, onboarding, and MSA frameworks, signals a scaling operations play. Pain points around training new writers, budget delivery, and managing complex international accounts suggest the company is wrestling with execution complexity as it grows across geographies.
Cactus Life Sciences partners with global biopharma companies to translate complex scientific research into actionable medical communications and regulatory content. The firm operates across medical information, clinical evaluation reports, health economics and outcomes research (HEOR), literature surveillance, and scientific publications. With 1,001–5,000 employees based in the US, UK, Switzerland, India, and Japan, CLS handles high-touch account work including multi-million-dollar engagements, custom training programs for pharma medical affairs teams, and interactive regulatory assets. The business model relies on experienced medical writers and project delivery against fixed scopes and master service agreements.
CLS actively recruits across the United States, United Kingdom, India, Switzerland, Japan, Singapore, Germany, South Korea, and Taiwan, reflecting its global footprint and distributed delivery model.
Current priorities include scientific setup of new account teams, intensive onboarding programs, annual training plans for pharma clients, webinars for medical affairs teams, MSA framework implementation, and development of costing models for new AI services.
The company operates on Microsoft Office (Excel, Word, PowerPoint, SQL), with specialized research tools including PubMed, EndNote, and Mendeley for literature management and scientific content development.
Other companies in the same industry, closest in size